Discovery of novel benzoquinazolinones and thiazoloimidazoles, inhibitors of influenza H5N1 and H1N1 viruses, from a cell-based high-throughput screen

Journal of Biomolecular Screening

Volumn 16, Issue 1, 2011, Pages 73-81

  Maddry, Joseph A ^a   Chen, Xi ^a   Jonsson, Colleen B ^a,b   Ananthan, Subramaniam ^a   Hobrath, Judith ^a   Smee, Donald F ^c   Noah, James W ^a   Noah, Diana ^a   Xu, Xiaolin ^a   Jia, Fuli ^a   Maddox, Clinton ^a   Sosa, Melinda I ^a   White, E Lucile ^a   Severson, William E ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b University of Louisville School of Medicine   (United States)

^c UTAH STATE UNIVERSITY   (United States)

Author keywords

1 benzoyl 3 arylthioureas; anti infective drugs; automation robotics; benzothiazinones; carboxanilides; cell based assays; HTS; influenza virus; sulfonamides

Indexed keywords

ANTIVIRUS AGENT; BENZOQUINAZOLINONE DERIVATIVE; THIAZOLOIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOG; DOSE RESPONSE; HIGH THROUGHPUT SCREENING; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIVIRAL AGENTS; BIRDS; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; DOGS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMIDAZOLES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; QUINAZOLINONES; RNA; SMALL MOLECULE LIBRARIES; THIAZOLES; VIRUS REPLICATION;

ORTHOMYXOVIRIDAE;

EID: 78951486960     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110384613     Document Type: Article

References (33)

1. Ford SM, Grabenstein JD: Pandemics, avian influenza A (H5N1), and a strategy for pharmacists. Pharmacotherapy 2006 ; 26: 312-322.
2. van Riel D., Munster VJ, de Wit E., Rimmelzwaan GF, Fouchier RA, Osterhaus AD,, et al. H5N1 virus attachment to lower respiratory tract. Science 2006 ; 312: 399-400.
3. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H.,, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998 ; 279: 393-396.
4. Melidou A.: Avian influenza A (H5N1): current situation. Euro Surveill 2009 ; 14 (18). 19199.
5. Webster RG, Govorkova EA: H5N1 influenza: continuing evolution and spread. N Engl J Med 2006 ; 355: 2174-2177.
6. Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R., Chen WH,, et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009 ; 27: 5091-5095.
7. Noah DL, Hill H., Hines D., White EL, Wolff MC: Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol 2009 ; 16: 558-566.
8. Nicholson KG, Colegate AE, Podda A., Stephenson I., Wood J., Ypma E.,, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001 ; 357: 1937-1943.
9. Fodor E., Devenish L., Engelhardt OG, Palese P., Brownlee GG, Garcia-Sastre A.: Rescue of influenza A virus from recombinant DNA. J Virol 1999 ; 73: 9679-9682.
10. Hoffmann E., Krauss S., Perez D., Webby R., Webster RG: Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 2002 ; 20: 3165-3170.
11. Neumann G., Watanabe T., Ito H., Watanabe S., Goto H., Gao P.,, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 1999 ; 96: 9345-9350.
12. Bresson JL, Perronne C., Launay O., Gerdil C., Saville M., Wood J.,, et al. Safety and immunogenicity of an inactivated split-virion influenza A/ Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006 ; 367: 1657-1664.
13. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E.,, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007 ; 370: 580-589.
14. Treanor JJ, Campbell JD, Zangwill KM, Rowe T., Wolff M.: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006 ; 354: 1343-1351.
15. Vajo Z., Wood J., Kosa L., Szilvasy I., Paragh G., Pauliny Z.,, et al. A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development. J Virol 2010 ; 84: 1237-1242.
16. Lew W., Chen X., Kim CU: Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr Med Chem 2000 ; 7: 663-672.
17. von Itzstein M., Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B.,, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993 ; 363: 418-423.
18. Davies WL, Grunert RR, Haff RF, McGahen JW, Neumayer EM, Paulshock M.,, et al. Antiviral activity of 1-adamantanamine (amantadine). Science 1964 ; 144: 862-863.
19. Privatdegarilhe M., De Rudder J.: Effect of 2 arabinose nucleosides on the multiplication of herpes virus and vaccine in cell culture [in French]. C R Hebd Seances Acad Sci 1964 ; 259: 2725-2728.
20. Palese P., Shaw ML: Orthomyxoviridae: the viruses and their replication. In Knipe DM (ed): Fields Virology. Philadelphia: Wolters Kluwer / Lippincott Williams & Wilkins ; 2007: 1647-1690.
21. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009 ; 58: 969-972.
22. Hurt AC, Ernest J., Deng YM, Iannello P., Besselaar TG, Birch C.,, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009 ; 83: 90-93.
23. Wang SY, Su CY, Lin M., Huang SY, Huang WI, Wang CC,, et al. HA-pseudotyped retroviral vectors for influenza antagonist screening. J Biomol Screen 2009 ; 14: 294-302.
24. Eichelberger MC, Hassantoufighi A., Wu M., Li M.: Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. Virol J 2008 ; 5: 109-113.
25. Noah JW, Severson W., Noah DL, Rasmussen L., White EL, Jonsson CB: A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res 2007 ; 73: 50-59.
26. Eriksson B., Helgstrand E., Johansson NG, Larsson A., Misiorny A., Noren JO,, et al. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 1977 ; 11: 946-951.
27. Sidwell RW, Huffman JH: Use of disposable micro tissue culture plates for antiviral and interferon induction studies. Appl Microbiol 1971 ; 22: 797-801.
28. Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW: Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 2001 ; 45: 743-748.
29. Blick TJ, Tiong T., Sahasrabudhe A., Varghese JN, Colman PM, Hart GJ,, et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995 ; 214: 475-484.
30. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
31. Severson WE, McDowell M., Ananthan S., Chung DH, Rasmussen L., Sosa MI,, et al. High-throughput screening of a 100,000-compound library for inhibitors of influenza A virus (H3N2). J Biomol Screen 2008 ; 13: 879-887.
32. Gupta RK, Nguyen-Van-Tam JS: Oseltamivir resistance in influenza A (H5N1) infection. N Engl J Med 2006 ; 354: 1423-1424 ; author reply 1423-1424.
33. Bright RA, Shay DK, Shu B., Cox NJ, Klimov AI Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006 ; 295: 891-894.